Vaccines and immuno-therapeutics for the prevention and treatment of bacterial diseases, including hospital-acquired (nosocomial) infections, food and waterborne infections (including traveler’s diarrhea), bacterial biowarfare agents, urinary tract infections, and wound infections. Syntiron is pleased to be engaged in a strategic partnership with sanofi pasteur for the development of its Staphylococcus vaccine.

Bacterial diseases pose a serious threat to human health world-wide. They also pose an increasing economic threat as healthcare costs continue to escalate in both developed and emerging economies.

Read more about Syntiron’s market potential

Syntiron’s patented vaccine technology is based on the use of defined bacterial cell surface components as target antigens for vaccine and immunotherapeutic development. This technology has been successfully established for use in veterinary healthcare. Syntiron is currently developing the technology for several areas of human healthcare.

Read more about Syntiron’s platform technology